BioSpace News Archive

At the American Society of Nephrology’s (ASN) Kidney Week 2023, Bayer today announced pharmacodynamic data on Kerendia® (finerenone), the first non-steroidal, selective mineralocorticoid receptor (MR) antagonist to demonstrate dual cardiorenal risk reduction in adult patients with chronic kidney disease (CKD) and type 2 diabetes (T2D).

Vivos Therapeutics, Inc., a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild-to-moderate obstructive sleep apnea and snoring in adults, announced that it has closed a $4 million private placement previously announced on October 31, 2023.